Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211265 | 0.90 | HDAC6 (0.48) | HDAC6HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL16211665 | 0.90 | HDAC6 (0.48) | HDAC6HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL16211267 | 0.90 | HDAC6 (0.48) | HDAC6HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL16211344 | 0.81 | HDAC6 (0.52) | HDAC6HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL16211681 | 0.81 | HDAC6 (0.52) | HDAC6HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL16211342 | 0.81 | HDAC6 (0.52) | HDAC6HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL25979867 | 0.80 | HDAC6 (0.47) | HDAC6HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL25981501 | 0.80 | HDAC6 (0.49) | HDAC6HDAC8HDAC1HDAC3HDAC11 | |
| SCHEMBL25981478 | 0.80 | HDAC6 (0.47) | HDAC6HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL16221514 | 0.79 | DPP4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248735-A1 | COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248735-A1 | COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) | NR1H2, CFTR, CYP11B2 | HDAC6 997/4885HDAC8 2983/4885HDAC1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.